EGFR blood monitoring

Patent metadata

Field	Value
Publication number	US-9914975-B2
Application number	US-201615098150-A
Country	US
Kind code	B2
Filing date	Apr 13, 2016
Priority date	Mar 8, 2013
Publication date	Mar 13, 2018
Grant date	Mar 13, 2018

Abstract

Improved methods of assessing status of a solid-tumor cancer in a subject involving detection of tumor-associated mutations in the subject's blood.

First claim

The invention claimed is:

1. A method of treating a non-small cancer cell lung cancer (NSCLC) patient with a targeted drug therapy, comprising:
(a) carrying out a PET scan on the NSCLC patient and assessing metastatic status of the NSCLC patient as M1a or M1b;
(b) based on the assessment in step (a), sorting the NSCLC patient as having metastatic status M1a or M1b;
(c)(i) obtaining a tumor tissue sample from the NSCLC patient having metastatic status M1a and detecting presence or absence of one or more mutated Epidermal Growth Factor Receptor (EGFR) sequence in the tumor tissue sample from the NSCLC patient by allele-specific PCR;
(c)(ii) obtaining a blood sample, and not a tumor tissue sample, from the NSCLC patient having metastatic status M1b and detecting presence or absence of one or more mutated Epidermal Growth Factor Receptor (EGFR) sequence in the blood sample from the NSCLC patient by allele-specific PCR; and
(d) if the presence of an activating EGFR mutation selected from the group consisting of exon 19 deletion, L858R, L861Q, and G719X is detected, administering targeted drug therapy to the NSCLC patient, wherein the targeted drug therapy is an EGFR tyrosine kinase inhibitor.

2. The method of claim 1 , wherein the one or more mutated EGFR sequence comprises a resistance EGFR mutation selected from the group consisting of T790M, S678I and an exon 20 insertion.

3. The method of claim 2 , wherein the tyrosine kinase inhibitor is an irreversible tyrosine kinase inhibitor.

4. The method of claim 1 , wherein the tyrosine kinase inhibitor is erlotinib of gefitinib.

5. The method of claim 1 , wherein the presence or absence of one or more mutated EGFR sequence in the blood of the NSCLC patient subject is detected more than one time before, during, or after targeted drug therapy, or any combination thereof.

6. The method of claim 5 , increasing the dose of tyrosine kinase inhibitor administered to the NSCLC patient if an increase in quantity of the activating EGFR mutation selected from the group consisting of exon 19 deletion, L858R, L861Q, and G719X is detected.

7. The method of claim 1 , further comprising modifying the targeted drug therapy.

8. The method of claim 2 , further comprising modifying the targeted drug therapy.

9. The method of claim 5 , further comprising modifying the targeted drug therapy.

Assignees

• Roche Molecular Systems Inc
• Univ Aarhus

Inventors

• Meldgaard Peter
• Sorensen Boe
• Tsai Julie
• Wen Wei
• Wu Lin

Classifications

• A61K31/517

  ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title